Physicians, scientists, genetic counselors, and allied health staff from Mayo Clinic and Mayo Medical Laboratories are currently attending the American College of Cardiology (ACC) Annual Meeting in Washington, D.C.
In addition to being represented by numerous presentations and abstracts, Mayo Medical Laboratories representatives will be available at booth #2903 in the exhibit hall to discuss:
EVIDENCE-BASED TESTING APPROACHES FOR CORRECT DIAGNOSES AND TREATMENT
Our unique combination of subspecialty laboratories and cardiology patient-care clinics has enabled the development of tests and testing approaches that have clinically proven outcomes and third-party validation showing reduced costs across an episode of care.
A NOVEL BIOMARKER OF UNSTABLE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Ceramides are complex lipids that play a central role in cell membrane integrity, cellular stress response, inflammatory signaling, and apoptosis. Synthesis of ceramides from saturated fats and sphingosine occurs in all tissues. Ceramides accumulate in tissues not suited for lipid storage during conditions of metabolic dysfunction and dyslipidemia. Three specific ceramides have been identified as highly linked to cardiovascular disease: Cer(16:0), Cer(18:0), Cer(24:1).
Featured Poster Presentation:
Plasma Ceramide Concentrations Predict Risk of Cardiovascular Events
CV Pharmacogenomics Testing
MAXIMIZE EFFICACY AND MINIMIZE ADVERSE EVENTS OF COMMON CV THERAPIES
The drugs available today to treat cardiovascular disease are powerful agents that work as intended in most patients. Yet, in some people, a particular drug at the standard dose might not work well enough or may even trigger a serious adverse reaction. This can be due to genetic causes, which often play an important role in a patient’s predisposition to experiencing adverse drug reactions or therapeutic failure.
- Cytochrome P450 2D6 (CYP2D6) Comprehensive Cascade, Blood (2D6CB) Test Sheet
- Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) Genotype, Statin, Blood (SLC1B) Test Sheet
CV Next-Generation Sequencing Panels
TESTING FOR CARDIOMYOPATHIES, NOONAN, LONG QT, BRUGADA, MARFAN SYNDROMES, AND RELATED DISORDERS
Next-generation sequencing (NGS) is a form of genetic analysis that allows the laboratory to analyze a large number of genes in a more efficient manner compared to other technologies. NGS technology has been increasingly used for a number of genetic conditions that display allelic and locus heterogeneity, such as cancer and inherited cardiac disorders.
Mayo Clinic Presentations
5:30 p.m.–5:45 p.m.
913-06 - NPA7, a First in Class Dual Receptor Activator with Cardio-Renoprotective Properties In Vivo
9:17 a.m.–9:27 a.m.
912-14 - Isolated Tricuspid Valve Surgery: Repair Versus Replacement
MODERATED POSTER CONTRIBUTIONS
10 a.m.–10:10 a.m.
1132M-03 - Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis
10:30 a.m.–10:40 a.m.
1134M-07 - CHA2DS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in a Referral Population
11 a.m.–11:10 a.m.
1131M-11 - Outcomes of Non-Cardiac Procedures in Adult Fontan Patients
11:30 a.m.–11:40 a.m.
1132M-15 - Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients with Severe Aortic Stenosis
3:45 p.m.–3:55 p.m.
1173M-03 - Digital Health Intervention Usage Improves Weight Loss in a Dose-Dependent Fashion
3:45 p.m.–3:55 p.m.
1260M-03 - Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study
4:15 p.m.–4:25 p.m.
1264M-07 - E/e’ Short- and Long-Term Independent Prognostic Role in Patients with Left Ventricular Dysfunction
10:15 a.m.–10:25 a.m.
1304M-07 - Familial Hypercholesterolemia: Awareness, Detection, and Control in the Community
12:45 p.m.–12:55 p.m.
1318M-05 - Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes after Heart Transplantation: A Single Center 15-Year Follow-Up Study
1:15 p.m.–1:25 p.m.
1319M-09 - Coronary Artery Disease Patients with Concurrent Psychiatric Disorders at Greater Risk for Mortality
1:30 p.m.–1:40 p.m.
1316M-11 - Long-Term Outcomes of Patients Undergoing Percutaneous and Surgical Mitral Paravalvular Leak Repair